Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib atezolizumab combination study in advanced or metastatic solid tumors
NL-OMON47714Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab, ipilimumab, interferon alfa-2b, peginterferon alfa-2a, bevacizumab and 1 more in non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC) and 3 more (5 arms), sponsored by Roche. Primary endpoints: Dose-limiting toxicities, Adverse events and 7 more. Started Feb 2015; status: active, not recruiting.
02
Drugs
atezolizumabipilimumabinterferon alfa-2bpeginterferon alfa-2abevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)melanomarenal cell carcinoma (RCC)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON47714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47714.